scPharmaceuticals (SCPH) Stock Price, News & Analysis

Company Overview

scPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing improved formulations of established oncology therapies through its proprietary SoluMatrix® microcrystal platform. By generating submicron drug particles, the company aims to enhance solubility, reduce infusion times and mitigate adverse reactions commonly associated with high-dose chemotherapy. Its technology is designed to repurpose widely used cytotoxic agents, offering the potential to address unmet needs in cancer treatment without the lengthy timelines required for novel drug discovery.

The company’s lead candidate, SM-101, is a reformulated injectable version of gemcitabine being evaluated in Phase I/II studies for pancreatic and non-muscle invasive bladder cancer. SM-101 has received orphan drug designation from the U.S. Food and Drug Administration for pancreatic cancer, and early clinical results have demonstrated encouraging tolerability and preliminary efficacy signals. In addition to SM-101, scPharmaceuticals is advancing a second oncology program based on a reengineered formulation of paclitaxel, with the goal of reducing infusion-related side effects and broadening patient eligibility for treatment.

Founded in 2009 and headquartered in Bridgewater, New Jersey, scPharmaceuticals conducts its clinical operations across the United States and Europe. The company is led by a management team with extensive experience in oncology development, regulatory affairs and pharmaceutical manufacturing. Under the leadership of CEO Suneel Chilukuri and supported by a board comprising former executives from major pharmaceutical firms, scPharmaceuticals is positioned to leverage its microcrystal technology to potentially improve standard-of-care cancer treatments and deliver value for patients and shareholders alike.

Key Stats

• Today's Range: $3.99 to $4.18
• 50-Day Range: $2.24 to $4.27
• 52-Week Range: $1.94 to $5.65
• Volume: 264,990 shs
• Average Volume: 374,471 shs
• Market Capitalization: $215.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

scPharmaceuticals Stock Analysis - MarketRank™

scPharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 172nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

scPharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of scPharmaceuticals is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of scPharmaceuticals is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

scPharmaceuticals has a P/B Ratio of 15.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.64% of the float of scPharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

scPharmaceuticals has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in scPharmaceuticals has recently decreased by 12.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

scPharmaceuticals does not currently pay a dividend.

Dividend Growth

scPharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

3.64% of the float of scPharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

scPharmaceuticals has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in scPharmaceuticals has recently decreased by 12.02%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for SCPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.78% of the stock of scPharmaceuticals is held by insiders.

Percentage Held by Institutions

89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCPH Stock Analysis - Frequently Asked Questions

How have SCPH shares performed this year?

scPharmaceuticals' stock was trading at $3.54 at the beginning of the year. Since then, SCPH shares have increased by 15.3% and is now trading at $4.08.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals, Inc. (NASDAQ:SCPH) released its earnings results on Wednesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. The company earned $11.75 million during the quarter, compared to the consensus estimate of $11.63 million. scPharmaceuticals had a negative trailing twelve-month return on equity of 594.07% and a negative net margin of 216.24%.
Read the conference call transcript.

When did scPharmaceuticals IPO?

scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

How do I buy shares of scPharmaceuticals?

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of scPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/09/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCPH
• CIK: 1604950
• Web: www.scpharma.com
• Phone: (617) 517-0730
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for scPharmaceuticals: $14.00
• High Price Target: $18.00
• Low Price Target: $12.00
• Potential Upside/Downside: +243.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$85.15 million
• Net Margins: -216.24%
• Pretax Margin: -216.24%
• Return on Equity: -594.07%
• Return on Assets: -73.54%

Debt

• Debt-to-Equity Ratio: 3.86
• Current Ratio: 5.48
• Quick Ratio: 4.61

Sales & Book Value

• Annual Sales: $36.33 million
• Price / Sales: 5.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 15.11

Miscellaneous

• Outstanding Shares: 52,790,000
• Free Float: 50,269,000
• Market Cap: $215.38 million
• Optionable: Optionable
• Beta: 0.38